Chris Bly is a manager at Stratevi. He has over 14 years of experience in HEOR consulting, focusing on data synthesis and evidence generation in support of pharmacoeconomic modeling and value messaging. His work in the past ten years has focused on orphan drugs in oncology and targeted therapy in migraine treatment. He holds a chemistry degree from Wabash College.